Shanghai Bio-Heart Biological Technology Co., Ltd (HKG: 2185), a leading Chinese interventional cardiovascular device maker, will invest RMB 50 million (USD 7.2 million) in compatriot firm Cardiotek HK Ltd, securing a 9.09% stake. The deal underscores Bio-Heart’s expansion into transcatheter aortic valve replacement (TAVR) technology, complementing its core bioresorbable scaffold (BRS) and renal denervation (RDN) pipelines.
Cardiotek’s TAVR Innovation
Founded in 2017, Cardiotek specializes in minimally invasive cardiovascular devices, with its lead product being a balloon-expandable TAVR system. Unlike self-expanding TAVR devices on China’s market, Cardiotek’s offering features easier operation, precise implantation, lower coronary intervention risk, reduced paravalvular leakage, and fewer permanent pacemaker needs. The company plans to launch clinical trials by late 2023 or early 2024.
Bio-Heart’s Pipeline and Synergies
Bio-Heart, known for its in-house BRS system poised to become the world’s first second-generation bioresorbable scaffold, will leverage Cardiotek’s TAVR platform to diversify its portfolio. The firm also develops RDN therapies for hypertension, aligning with China’s growing demand for innovative cardiovascular solutions.
Strategic Outlook
The investment marks Bio-Heart’s push into structural heart disease, pairing its R&D strengths with Cardiotek’s TAVR expertise. With China’s aging population driving market growth, the partnership aims to deliver differentiated therapies for aortic stenosis and other cardiac conditions.-Fineline Info & Tech
